Teva Launches Generic High Blood Pressure Treatments

Teva Pharmaceutical Industries announced that it has launched sales of irbesartan and irbesartan-hydrochlorothiazide tablets, two generic versions of Sanofi Aventis’ high blood pressure treatments. According to the company, the brand products had annual sales of approximately $464 million and $124 million in the United States, based on sales data from the IMS research firm. In addition, Teva has been awarded a 180-day period of marketing exclusivity.